Clinical trials · Detroit, MI
Lung Diseases clinical trials in Detroit
We’re tracking 24 recruiting lung diseases studies with a site in or near Detroit — including Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Detroit
- NCT07051707Recruiting
Study of a new lung treatment for people with COPD
This trial tests a device called dNerva that targets nerves in the lungs to help people with COPD breathe easier. It is designed for those who have moderate to severe COPD and are not currently smoking.
Detroit, MichiganAges 40–80 - NCT06772623RecruitingPhase 1/Phase 2
Study of telisotuzumab adizutecan plus immunotherapy for advanced lung cancer
This trial tests a new combination treatment for people with advanced non-squamous non-small cell lung cancer who haven't received prior therapy for advanced disease and don't have specific gene changes. The treatment includes an antibody-drug conjugate (telisotuzumab adizutecan) plus an immunotherapy drug (PD-1 checkpoint inhibitor) to see if it helps shrink tumors and improve outcomes.
Detroit, MichiganAges 18 years+ - NCT01915511Recruiting
Long-term registry for new or worsening lung scarring
This study collects health information over time from people with newly diagnosed idiopathic pulmonary fibrosis (IPF) or other lung scarring diseases that are getting worse. It’s meant to better understand disease patterns and outcomes, which may help doctors plan future care.
Detroit, MichiganAges 21 years+ - NCT05592626RecruitingPhase 1/Phase 2
T cell activator STAR0602 for advanced solid tumors
This study tests an experimental drug called STAR0602 that aims to boost your immune system's T cells to fight advanced solid tumors. It's for patients whose cancer has not responded to standard treatments or for whom such treatments are not suitable.
Detroit, MichiganAges 18 years+ - NCT07473700RecruitingPhase 2
Study of TX000045 for lung scarring and high blood pressure in the lungs
This trial tests a new medicine called TX000045 for people who have both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug can help improve breathing and daily function.
Allen Park, MichiganAges 18–80 - NCT04905693Enrolling by invitationPhase 3
Extension inhaled treprostinil study for fibrotic lung disease
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
Royal Oak, MichiganAges 40 years+ - NCT05943535RecruitingPhase 3
Breathing treprostinil to slow progressive lung scarring
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
Royal Oak, MichiganAges 18 years+ - NCT06388421Recruiting
PH-ILD patient registry: tracking real-world outcomes
This study tracks people with both lung scarring and high blood pressure in the lungs (Group 3 PH-ILD) to better understand the disease and how treatments like Tyvaso work in real life. It may help you and your doctor make more informed decisions about your care.
Troy, MichiganAges 18 years+ - NCT04928846RecruitingPhase 3
Telisotuzumab vedotin vs docetaxel for advanced non-squamous lung cancer
This trial tests an investigational drug (telisotuzumab vedotin) against the standard chemotherapy docetaxel in people with a certain type of non-squamous lung cancer that has high levels of a protein called c-Met. It may offer a new treatment option for those whose cancer has progressed after initial therapy.
Ypsilanti, MichiganAges 18 years+ - NCT06855329Recruiting
Studying progressive lung scarring (non-IPF)
This study is for people with a specific type of lung scarring (not IPF) to understand how the disease progresses. Researchers will collect detailed health information, imaging, and blood samples to learn more about the condition.
Ann Arbor, MichiganAges 18–80 - NCT06397677Recruiting
Study of Progressive RA Interstitial Lung Disease
This study is looking at people with rheumatoid arthritis (RA) who also have interstitial lung disease (ILD), a condition that causes scarring in the lungs. It aims to understand how the disease changes over time by using imaging and blood tests, without providing any new treatments right now.
Ann Arbor, MichiganAges 18–90 - NCT04543461Recruiting
Lung health study for young adults in the U.S.
This study follows young adults to learn about lung health and risk factors. It may help researchers better understand how breathing symptoms and exposures affect future lung outcomes.
Ann Arbor, MichiganAges 25–35 - NCT06262282Enrolling by invitation
Phage therapy for stubborn NTM infection in cystic fibrosis
This trial tests whether a special virus therapy (phage) can help clear stubborn NTM lung infections in people with cystic fibrosis who have been on antibiotics for over a year without success. Participants will continue their antibiotics while receiving the phages.
Ann Arbor, MichiganAges 6 years+ - NCT06177717Recruiting
Lung Health Study for Young Adults
This study looks at how young adults' lungs work over time. It is a research visit where you'll complete breathing and other health tests to help understand lung health in people aged 25–35.
Ann Arbor, MichiganAges 25–35 - NCT06195072RecruitingPhase 2
Platform study for scleroderma with lung disease
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
Ann Arbor, MichiganAges 18 years+ - NCT07482475Recruiting
COPD study for people getting lung cancer screening
This study looks at COPD in people who are already getting lung cancer screening. If you have COPD or a high risk for it, joining this observational trial may help researchers learn more about your condition.
Ann Arbor, MichiganAges 50–80 - NCT07201922RecruitingPhase 3
Can a new pill help slow lung changes in people with family risk?
This trial tests a new drug called nerandomilast to see if it can slow down early lung changes in people who have a close family member with a type of lung scarring called pulmonary fibrosis. You may join if you are 40 or older, have a parent, sibling, or child with this condition, and have early signs of lung changes on a CT scan.
Ann Arbor, MichiganAges 40 years+ - NCT06911632Recruiting
AI-assisted check for pulmonary hypertension in interstitial lung disease
This study uses an AI tool to help doctors decide if you should be tested for pulmonary hypertension (high blood pressure in the lungs), which can be a complication of interstitial lung disease. If the tool suggests you might have it, you may get an echocardiogram (an ultrasound of the heart) and a right heart catheterization (a test to measure pressure in the heart) to find out for sure.
Ann Arbor, MichiganAges 18 years+ - NCT07175038RecruitingPhase 2
Study of a new pill for pulmonary hypertension
This study tests a new pill, ROC-101, for people with pulmonary hypertension (high blood pressure in the lungs). It aims to see if the pill can improve symptoms and daily function.
Ann Arbor, MichiganAges 18–80 - NCT05922761RecruitingPhase 2
Belumosudil for lung scar prevention or treatment after transplant
This Phase 2 study tests belumosudil to treat or prevent bronchiolitis obliterans (BOS), a lung complication that can happen after a stem cell transplant. If you qualify, you would be checked closely with breathing tests and scans, and watched for safety and whether lung function improves or stays stable.
Ann Arbor, MichiganAges 18 years+ - NCT05878717RecruitingPhase 2/Phase 3
Belimumab for adults with scleroderma lung scarring
This Phase 2/3 study tests whether belimumab can improve outcomes and safety in adults with systemic sclerosis (scleroderma) that has caused lung scarring. It may help by reducing active or worsening immune-driven disease in the lungs.
Ann Arbor, MichiganAges 18 years+ - NCT06328777RecruitingPhase 2/Phase 3
Testing a new immune cell therapy for systemic sclerosis (scleroderma)
This trial tests a new treatment called CABA-201, which uses your own immune cells to target and calm the overactive immune system causing scleroderma. It aims to reduce symptoms and slow or stop the disease's progression.
Ann Arbor, MichiganAges 18–75 - NCT05866302Recruiting
CT breathing-scan test to detect chronic lung injury after transplant
This study uses a special way to analyze breathing-related CT images to find early or ongoing lung injury after an allogeneic stem cell transplant. It may help clinicians recognize chronic lung complications sooner and better guide care.
Ann Arbor, MichiganAges 3 years+ - NCT06129240Recruiting
Study of a new inhaled treprostinil powder for PH-ILD
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
Ann Arbor, MichiganAges 18–80
Hear when a new Lung Diseases trial opens near Detroit, MI
We’ll email you when one opens near Detroit, MI — at most once a week, no account needed, unsubscribe anytime.
Lung Diseases trials in other cities
Where these studies are running near Detroit
Institutions with a site for the recruiting lung diseases studies listed above.
- University of Michigan · 16 studies
- Henry Ford Health · 3 studies
- Corewell Health William Beaumont University Hospital · 2 studies
- Allen Park
- Corewell Health Beaumont Troy Hospital
- GSK Investigational Site
- Trinity Health Ann Arbor Hospital
- Wayne State University/Karmanos Cancer Institute
What taking part in a lung diseases study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting lung diseases studies in Michigan.
Common questions
- Are there lung diseases clinical trials near Detroit?
- Yes. We're currently tracking 24 recruiting lung diseases studies with a site near Detroit, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a lung diseases study near Detroit?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Detroit to take part?
- Not necessarily. These studies have a site near Detroit, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a lung diseases trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New lung diseases studies open near Detroit regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.